Routine Health Screening Market Report 2026

The routine health screening market size has grown strongly in recent years. It will grow from $58.45 billion in 2025 to $62.9 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to increasing public health awareness, expansion of diagnostic laboratory networks, rising incidence of chronic diseases, improved access to basic healthcare services, growing employer-sponsored health screening initiatives.

The routine health screening market size is expected to see strong growth in the next few years. It will grow to $83.35 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to growing adoption of personalized preventive care, rising demand for remote and home-based diagnostics, expansion of digital health platforms, increasing use of advanced screening technologies, growing emphasis on population health management. Major trends in the forecast period include increasing adoption of preventive health screening programs, growing use of home-based diagnostic testing, expansion of digital health records integration, rising focus on early disease detection, enhanced accessibility of routine screening services.

The growing emphasis on preventive healthcare is expected to drive the expansion of the routine health screenings market in the coming years. Preventive healthcare encompasses measures and practices designed to prevent the development or progression of diseases and health conditions through early detection, lifestyle changes, and proactive interventions. The rising awareness of preventive healthcare is fueled by its advantages in early disease identification, improved health outcomes, and cost efficiency, supported by enhanced public education and medical advancements. Routine health screenings support preventive healthcare by detecting potential health issues early, enabling timely interventions, and lowering the risk of severe illnesses. For example, in May 2023, the National Health Service (NHS), a UK-based publicly funded healthcare system, reported that 2,302,400 diagnostic tests were conducted in March 2023, representing an increase of 223,100 tests compared to March 2022. By the end of March 2023, the number of patients awaiting a key diagnostic test reached 1,628,300, an increase of 59,400 from March 2022. Consequently, the rising awareness of preventive healthcare is contributing to the growth of the routine health screenings market.

Major companies operating in the routine health screenings market are concentrating on developing advanced solutions, such as lung cancer screening tests, to strengthen their market position. Lung cancer screening tests are medical assessments designed to detect lung cancer at an early stage in individuals who may be at high risk, even before symptoms manifest. For example, in October 2023, DELFI Diagnostics Inc., a US-based diagnostic technology company, introduced FirstLook Lung, an innovative blood test aimed at enhancing lung cancer screening. Using fragmentomics, FirstLook Lung examines patterns in cell-free DNA (cfDNA) from blood samples and leverages advanced machine learning to distinguish between cancerous and non-cancerous patterns. With a 99.7% negative predictive value (NPV), the test efficiently identifies potential lung cancer cases while reducing the need for unnecessary low-dose CT (LDCT) scans. Integrated into routine blood tests, FirstLook Lung seeks to improve screening rates, particularly among underserved populations, and features a scalable whole-genome machine-learning platform with potential for global expansion into other cancers and treatment monitoring.

In March 2024, Laboratory Corporation of America Holdings, a US-based healthcare and diagnostics company, acquired BioReference Health from OPKO Health Inc. for $237.5 million. The acquisition is intended to enhance Labcorp's access to and capabilities in routine health screening. BioReference Health is a US-based diagnostic laboratory company that offers testing services, including routine health screenings, oncology, urology, and reproductive and women's health tests.

Major companies operating in the routine health screening market are Roche Holding AG, Thermo Fisher Scientific Inc., Siemens Healthineers, Laboratory Corporation, Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Sonic Healthcare Limited, Hologic Inc., Illumina Inc., SYNLAB International GmbH, Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, RadNet Inc., Opko Health Inc., UNILABS, Amedes Holding GmbH, Natera Inc., Grail Inc., Trinity Biotech PLC, Cerba HealthCare S.A.S., Quidel Corporation, Innova Medical Group.

North America was the largest region in the routine health screening market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the routine health screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the routine health screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the routine health screening market by increasing costs of imported diagnostic instruments, reagents, imaging equipment, and laboratory consumables used across hospitals and diagnostic centers. North America and Europe are most affected due to dependence on imported testing technologies, while developing regions face higher screening program costs. These tariffs are raising operational expenses and impacting test affordability. However, they are also supporting local manufacturing of diagnostic kits, regional laboratory expansion, and domestic innovation in cost-efficient screening solutions.

The routine health screening market research report is one of a series of new reports that provides routine health screening market statistics, including routine health screening industry global market size, regional shares, competitors with a routine health screening market share, detailed routine health screening market segments, market trends and opportunities, and any further data you may need to thrive in the routine health screening industry. This routine health screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Routine health screening involves regular medical tests and check-ups designed to detect potential health problems early, often before any symptoms appear. These screenings help track overall health, identify risk factors, and prevent the onset of serious conditions such as heart disease, diabetes, or cancer. They are generally recommended based on factors like age, gender, and medical history and play a vital role in supporting long-term health and well-being.

The primary types of tests in routine health screening include blood glucose tests, kidney function tests, bone profile tests, electrolyte tests, liver function tests, lipid profile tests, and others. A blood glucose test evaluates the level of glucose (sugar) in the blood to screen for diabetes or monitor its treatment. Samples can include blood, urine, serum, saliva, and more, and the technologies used include quantitative polymerase chain reaction (QPCR), quantitative fluorescence in situ hybridization (Q-FISH), immunoassays, medical imaging, single telomere length analysis (STELA), and others. Sample collection can take place at hospitals, homes, diagnostic laboratories, offices, and other locations.

The routine health screening market consists of revenues earned by entities by providing services such as health assessments, screening procedures, consultations, telehealth screenings, and corporate wellness programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The routine health screening also includes sales of diagnostic test kits, medical devices, wearable health devices, and laboratory testing supplies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.